Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclopentolate is a small molecule anticholinergic (antimuscarinic) drug used primarily in ophthalmology to induce mydriasis (pupil dilation) and cycloplegia (paralysis of the ciliary muscle), facilitating diagnostic procedures such as eye examinations and refraction testing. It acts by blocking muscarinic acetylcholine receptors in the eye—specifically on the sphincter muscle of the iris and the ciliary body—leading to relaxation of these muscles. This results in rapid pupil dilation and loss of accommodation for near vision. The onset is typically within 15–60 minutes after topical application with effects lasting up to 24 hours or longer in some individuals. Cyclopentolate is available only by prescription[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclopentolate.